Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry

Ennio Giulio Favalli ¹, Antonio Marchesoni ¹, Silvia Balduzzi ², Carlomaurizio Montecucco ³, Claudia Lomater ⁴, Gloria Crepaldi ⁴, Silvia Tamanini ⁵, Chiara Bazzani ⁶, Enrico Fusaro ⁷, Marta Priora ⁷, Aurora Ianniello ⁸ and Roberto Caporali¹, ¹University of Milan, Department of Rheumatology, ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ²Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Lombardia, Italy, ³Department of Rheumatology, IRCCS Policlinico S. Matteo Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ⁴AO Ordine Mauriziano, SSD Reumatologia, Torino, Turin, Piemonte, Italy, ⁵ASST Spedali Civili and University of Brescia, Milan, Lombardia, Italy, ⁶Rheumatology and Clinical Immunology, Spedali Civili, Brescia, Italy, Brescia, Italy, ⁷A.O.U. Città della Salute e della Scienza di Torino, SC Reumatologia, Turin, Piemonte, Italy, ⁸Day Hospital Multidisciplinare PO SS. Trinità, Borgomanero, Borgomanero, Piemonte, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, Psoriatic arthritis, treatment and Biologic agents

Session Information

Date: Monday, November 11, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Observational data on the use of secukinumab for the treatment of spondyloarthritides are still lacking. The aim of this study is to evaluate the effectiveness and the 3-year retention rate of secukinumab in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients in a real-life setting.

Methods: Data of all PsA and axSpA patients (diagnosed according to CASPAR and ASAS criteria, respectively) treated with secukinumab were prospectively collected in the Italian multicentric LORHEN registry. Effectiveness was measured as the mean change from baseline of Disease Activity in PSoriatic Arthritis score (DAPSA) in PsA and Ankylosing Spondylitis Disease Activity Score (ASDAS) in axSpA patients. Rates of DAPSA remission and ASDAS inactive disease were also computed. The 3-year retention rate was calculated by the Kaplan-Meier method and compared between PsA and axSpA by a log-rank test. A descriptive analysis of reasons for discontinuation was performed.

Results: The study population included 195 PsA (55.4% females, mean age 50.7 [±11.8] years, mean disease duration 10 [±7.8] years, mean baseline DAPSA 23.12 [±12.3]) and 94 axSpA (61.7% males, mean age 49.1 [±12.7] years, mean disease duration 10.4 [±9.4] years, mean baseline ASDAS 3.41 [±1.1]) patients who received secukinumab as first (26.5 and 33%, respectively) or subsequent biologic agent. Compared with baseline, the 3-, 6- and 12-month mean values of both DAPSA (12.6 [±9], 11.2 [±10.5] and 9.3 [±7.5], respectively) and ASDAS (2.23 [±0.9], 2.15 [±0.9], and 1.84 [±0.9], respectively) were significantly decreased (p< 0.001 for all the timepoints). The 3-, 6-, and 12-month rates of remission/inactive disease were 15.5, 25.4, and 30.5% in PsA and 18, 23.7, and 28.6% in axSpA group, respectively. One- and 3-year retention rate (figure 1) were respectively 79.4% and 66.6% in PsA and 72.3% and 70.1% in axSpA patients, with no significant difference between the two groups (p=0.517). The most frequent reason for withdrawal was inefficacy in both PsA (n=41) and axSpA (n=20), whereas only 8 PsA and 6 axSpA patients discontinued secukinumab because of adverse events.

Conclusion: Our real-life data confirmed the effectiveness and the favorable safety profile of secukinumab for both PsA and axSpA, resulting in a high 3-year retention rate.

Figure 1: secukinumab retention rate in PsA and axSpA patients.

Disclosure: E. Favalli, None; A. Marchesoni, None; S. Balduzzi, None; C. Montecucco, None; C. Lomater, None; G. Crepaldi, None; S. Tamanini, None; C. Bazzani, None; E. Fusaro, None; M. Priora, None; A. Ianniello, None; R. Caporali, None.

To cite this abstract in AMA style:

Favalli E, Marchesoni A, Balduzzi S, Montecucco C, Lomater C, Crepaldi G, Tamanini S, Bazzani C, Fusaro E, Priora M, Ianniello A, Caporali R. Effectiveness and Retention Rate of Secukinumab for Psoriatic Arthritis and Axial Spondyloarthritis: Real-life Data from the Italian LORHEN Registry [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effectiveness-and-retention-rate-of-secukinumab-for-psoriatic-arthritis-and-axial-spondyloarthritis-real-life-data-from-the-italian-lorhen-registry/. Accessed .

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effectiveness-and-retention-rate-of-secukinumab-for-psoriatic-arthritis-and-axial-spondyloarthritis-real-life-data-from-the-italian-lorhen-registry/